Novel Alzheimer's Drug Passes First Phase of Human Testing

A new Alzheimer's drug has successfully passed the first phase of human testing, reports Medical News Today . PRI-002 purges toxic beta-amyloid oligomers suspected of causing and advancing Alzheimer's. Researchers previously demonstrated in a preclinical study published in Molecular Neurobiology that PRI-002 could significantly alleviate symptoms in older mice that were genetically engineered to develop an Alzheimer's-like disease with the addition of a mutant human gene. For the more recent trial, healthy volunteers took daily doses of PRI-002 for four weeks. "Our next goal is the proof of efficacy in people with Alzheimer's," said Forschungszentrum Jülich Professor Dieter Willbold. The next clinical phase is planned to be conducted through Priavoid, a private company that the scientists founded in 2017 to develop drugs for treating severe neurological conditions.